Phase 3 N=336 Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
Ischemic Stroke
Primary: Good Functional Recovery — 84; 68 patients — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=300 A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation
Infertility
Primary: Number of Oocytes Retrieved — 9.0; 9.0 Oocytes Retrieved
Phase 3 N=310 Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE
Massive Pulmonary Embolism
Primary: Death From All Causes — 3; 4 Participants — p=<0.05
Phase 3 N=530 A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
Respiratory Syncytial Viruses · Respiratory Syncytial Virus Infections
Primary: Adjusted Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies at 1 Month Post-second Dose of HZ/su Vaccination — 49326.9; 61192.7 mIU/mL
Phase 3 N=453 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
Schizophrenia
Primary: Negative Symptom Assessment-16 (NSA-16) Total Score - Change From Baseline to Week 26 — -12.14; -11.09 score on a scale — p=0.4825
Phase 3 N=1,426 Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
Herpes Zoster
Primary: Incidence Rate of Confirmed Herpes Zoster (HZ) Cases — 0.0; 4.1 Cases per 1000 person-years
Phase 3 N=26 An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
Generalized Myasthenia Gravis
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Main Treatment Period — 73.1 percentage of participants
Phase 3 N=355 Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
Renal Failure · End Stage Renal Disease · Hemodialysis
Primary: Number of Participants With Loss of Secondary Patency — 29; 34 Participants
Phase 3 N=41 A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
Atopic Dermatitis (AD)
Primary: Success Rate in IGA (Percentage of Subjects With an IGA Score of 0 or 1 With Improvement by at Least 2 Grades) — 56.10 Percentage of perticipants
Phase 3 N=149 Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
Kidney Diseases · Kidney Injury · Kidney Failure
Primary: Correlation of Transdermal Derived Glomerular Filtration Rate (tGFR) to the Plasma-derived Indexed Glomerular Filtration Rate (nGFR) — 0.950; 0.971 Proportion of tGFR…
Phase 3 N=100 Transabdominal Plane (TAP) Blocks for Inguinal Hernia Repairs
Inguinal Hernia
Primary: Pain Score at Rest — 4.31; 4.55; 4.21; 4.53 score on a scale
Phase 3 N=199 Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Chronic Myelogenous Leukemia
Primary: Major Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at Baseline — 42.35; 34.52 Percentage of responders
Phase 3 N=261 Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Primary: Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose — -2.70; -2.61 Scores on a scale — p=0.7782
Phase 3 N=1,066 Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
COPD
Primary: Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) — 0.248; 0.156; 0.138; -0.050 Litres — p=<0.001
Phase 3 N=120 A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
Cytomegalovirus Infection
Primary: Percentage of Participants With Clinically Significant Cytomegalovirus (CMV) Infection up to Week 24 Post-Transplant — 32 Percentage of Participants